Key facts
- This page summarizes Morgan Conn's Form 4 filing for Century Therapeutics, Inc. (IPSC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Mar 2025, 19:31.
Morgan Conn - 11 Mar 2025 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)
- Reporting relationship
- Chief Finanical Officer
- Issuer ticker
- IPSC
- Reported as of
- 11 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 19:31:34 UTC
- Prior SEC filing
- 16 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Morgan Conn
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Morgan Conn filed Form 4 for Century Therapeutics, Inc. (IPSC) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 16 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IPSC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,500
- Change %
- +32%
- Price
- $0.000000
- Shares after
- 79,648
- Date
- 11 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IPSC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +19,500
- Change %
- Price
- $0.000000
- Shares after
- 19,500
- Date
- 11 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,500
- Exercise price
- $0.6010
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
Footnote F2
The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.